Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Somatuline Autogel To Be Promoted By Tercica

This article was originally published in The Pink Sheet Daily

Executive Summary

Tercica gains the rights to the acromegaly treatment in the U.S. and Canada through a cross-licensing agreement with Ipsen, which receives European rights to Increlex.

You may also be interested in...



Ipsen Acquisition Trifecta Raises North American Stakes

French drug maker takes control of Tercica, Vernalis’ U.S. subsidiary and Octagen’s investigational hemophilia drug OB-1.

Ipsen Acquisition Trifecta Raises North American Stakes

French drug maker takes control of Tercica, Vernalis’ U.S. subsidiary and Octagen’s investigational hemophilia drug OB-1.

Tercica Acromegaly Therapy Will Launch In Two Months

Based on firm's $100 million sales projections, Somatuline Depot likely will be priced at $25,000 per patient.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel